Table 1

Patient demographics and disease characteristics

	C5b-9 positive (n=6)	C5b-9 negative (n=10)	P value
Female	4 (67)	8 (80)	0.60
Age, years	29.5 (17)	35 (21)	0.61
Ethnicity
Hispanic	3 (50)	2 (20)	0.30
Race
Asian	2 (33)	0	0.5
Black	0	4 (40)	0.23
White	0	2 (20)	0.50
Other	4 (66)	4 (40)	0.60
ISN/RPS LN Class*			0.58
III	3 (50)	2 (20)
IV	2 (33)	2 (20)
III/V	0	1 (10)
IV/V	1 (17)	2 (20)
V	0	2 (20)
Secondary APS	0	2 (20)	0.50
Asymptomatic aPL	2 (33)	3 (30)	1.0
Disease duration, years	5.5 (6)	10 (16.25)	0.12
SELENA SLEDAI	13 (11)	6 (12)	0.12
Non-renal SELENA SLEDAI	3 (4.5)	3 (3.5)	1.0
Serologically active	6 (100)	7 (70)	0.25
Active LN	5 (83)	3 (30)	0.04
NIH Activity Index†	7 (5)	7 (12)	1.0
NIH Chronicity Index†	3 (5)	2 (3)	1.0
IFTA (%)†	20 (21.9)	10 (25)	1.0
Laboratory tests
Albumin, g/dL	2.65 (1.1)	3.5 (1.3)	0.1
Adjusted dsDNA‡	4.95 (5.5)	2.5 (12.3)	0.32
C3, mg/dL	69.5 (63.8)	63 (48)	1.0
C4, mg/dL	18.5 (15.8)	20 (13.2)	1.0
Urine studies§
Red blood cells >5/hpf	4 (67)	3 (30)	0.30
uPCR	5.18 (5.1)	1.2 (2.06)	0.04
Active LN
	C5b-9 positive (n=5)	C5b-9 negative (n=3)
uPCR	5.18 (5.11)	0.8 (2.17)	0.001

Data are n (%) or median (IQR).
P values are evaluated using SPSS with t-tests or χ² tests of independence.
*One person LN Class missing.
†Three people without light microscopy details available.
‡Adjusted dsDNA calculated by dividing value by reference upper limit of normal.
§One person unable to provide urine due to being anuric.
dsDNA, double-stranded DNA; IFTA, interstitial fibrosis tubular atrophy; ISN/RPS, International Society of Nephrology and Renal Pathology Society; LN, lupus nephritis; NIH, National Institute of Health; SELENA SLEDAI, Safety of Estrogens in Systemic Lupus Erythematous National Assessment SLE Disease Activity Index; uPCR, urine protein creatinine ratio.